{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:53:06Z","timestamp":1772725986301,"version":"3.50.1"},"reference-count":31,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Bayer HealthCare Pharmaceuticals, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,1,26]]},"DOI":"10.1080\/14796694.2026.2614306","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:29:25Z","timestamp":1768818565000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and outcomes of patients with HCC treated with atezolizumab\/bevacizumab, stratified by second line therapy"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-3971","authenticated-orcid":false,"given":"Amit G.","family":"Singal","sequence":"first","affiliation":[{"name":"University of Texas Southwestern Medical Center","place":["Dallas, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3812-0692","authenticated-orcid":false,"given":"Kirhan","family":"\u00d6zg\u00fcrdal","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-6784","authenticated-orcid":false,"given":"Zdravko","family":"Vassilev","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals","place":["Whippany, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-2616","authenticated-orcid":false,"given":"Federica","family":"Pisa","sequence":"additional","affiliation":[{"name":"Bayer AG","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"John","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights, Cardinal Health","place":["Dublin, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-6124","authenticated-orcid":false,"given":"Taavy A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights, Cardinal Health","place":["Dublin, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8499-3059","authenticated-orcid":false,"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights, Cardinal Health","place":["Dublin, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gordon","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights, Cardinal Health","place":["Dublin, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-9994","authenticated-orcid":false,"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights, Cardinal Health","place":["Dublin, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6776-2015","authenticated-orcid":false,"given":"Xiaoyun","family":"Pan","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals","place":["Whippany, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.10.031"},{"key":"e_1_3_8_3_1","volume-title":"Cancer facts & figures 2024","author":"American Cancer Society (ACS)","year":"2024","unstructured":"American Cancer Society (ACS). Cancer facts & figures 2024. American Cancer Society; 2024."},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2018.78941"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab059"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14533"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2151891"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_430028"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000525582"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15789"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113264"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(24)00519-1"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34378"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.07.040"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000143"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15917"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1057"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1821"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12450"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000739"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000735"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502905"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000543666"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.033"},{"key":"e_1_3_8_31_1","volume-title":"Presented at International Liver Cancer Association (ILCA) Annual Conference","author":"Singal A","year":"2024","unstructured":"Singal A, Huang Y-H, Yoo C, et al. A prospective, observational study of the effectiveness of systemic therapies in patients with unresectable hepatocellular carcinoma following first-line immuno-oncology combination therapy (REFINE-IO). In: Presented at International Liver Cancer Association (ILCA) Annual Conference; Tor(ON)to, (ON), Canada; 2024."},{"key":"e_1_3_8_32_1","unstructured":"ClinicalTrials.gov. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251). Id: nct04770896. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04770896"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2614306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:51:53Z","timestamp":1772722313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2614306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,26]]}},"alternative-id":["10.1080\/14796694.2026.2614306"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2614306","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}